Illumina Inc (ILMN)

379.48
-1.55(-0.41%)
After Hours
379.94
+0.46(+0.12%)
- Real-time Data
  • Volume:
    754,724
  • Bid/Ask:
    378.00/387.00
  • Day's Range:
    375.98 - 381.94

ILMN Overview

Prev. Close
379.48
Day's Range
375.98 - 381.94
Revenue
3.47B
Open
380.08
52 wk Range
260.93 - 555.77
EPS
4.26
Volume
754,724
Market Cap
55.4B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,027,484
P/E Ratio
87.59
Beta
0.95
1-Year Change
13.28%
Shares Outstanding
146,000,000
Next Earnings Date
Aug 02, 2021
What is your sentiment on Illumina Inc?
or
Market is currently closed. Voting is open during market hours.

Illumina Inc News

  • Illumina appoints new CCO and CTO
    • BySeeking Alpha-

    Illumina has appointed Susan Tousi as chief commercial officer Alex Aravanis as chief technology officer, head of research and product development.

  • Illumina Earnings, Revenue Beat in Q1
    • ByInvesting.com-

    Investing.com - Illumina (NASDAQ:ILMN) reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations. Illumina announced earnings...

Illumina Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralBuySellBuy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong SellBuy
SummarySellSellStrong BuyStrong SellBuy

Illumina Inc Company Profile

Illumina Inc Company Profile

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Read More
  • should rise on earnings
    0
    • yeah "should"
      0
  • If the trial of Grail's Galeri test with the NHS is a success this stock is going to fly into the stratosphere. Imagine getting an early cancer test with your run of the mill blood draw at the doctors office. Billions in sales per month, millions of lives saved and reduced overall medical expenses. Watching this guy closely.
    1
    • Lol why keep falling tf
      0
      • when the share price go to 550 and above? i am waiting to sell my stock.
        0
        • ah too expensive bubble
          10
          • SNDL very cheap drugs company 0.51 USD that will reach 2 or 3 USD.. Other Drugs like Aurora reach 6USD.. Buying 5K shares and hold it is very good idea.. Good luck guys..
            0
            • Good call its right at $2.09 today.
              0
          • Wow, goes up everyday kind of stock, nice.
            0
            • Looking at all the downgrade today, it looks like nobody liked the fact Ilmn bought back something they  span off not long ago for 20% of their market cap, pretty amazingly they still went ahead and finish the deal. This Grail has to be really good, otherwise, the CEO's door is for him to exit.
              1
              • see 150
                5
                • Next stop 275, if not held, it will visit 200 March low. I don't think the recent drop is entirely Grail acquisition related. Sellers just use that as excuses. Two days down 8% each on very heavy volume, finished days at low,..
                  2
                  • Heavy volume? Its been averaging 1 mil of less only today was its volume above 4 million
                    0
                • Rather than bying Grail they should buy Guardant!
                  0
                  • On the way to make an acquisition, so it drops- I prefer Guardant even if expensive but they receive FDA approval both for covid test and cancer detectio liquid bloodtest
                    5
                    • too expensive
                      1
                      • Expensive for several reasons:  1) 70% of market share 2) consistently grow except during the pandemic 3) huge potential of the genetic field I'd love to see it drop to 200 again, but it will probably never see that price again unless they do a stock split.
                        0
                    • why it dropped so much so fast?
                      0
                      • Sundial growers next week 1,5 $
                        0
                        • 2019 july this stock drop 14%, same like today. looks like if wont hold 200 ema. usually sell off happen one or two days, not end in one day. high risk
                          1
                          • Huge buying opportunity
                            2
                            • not sure... i think 270-300 is possible
                              1
                            • really bad results. I think its gonna need a quarter to recover is upward trend.
                              1
                          • Buy now! Great moment!
                            4
                            • 3070430555638style picture
                              1
                              • JafarMalik9137132672
                                0
                                • ouch
                                  0
                                  • 330 tomorrow?
                                    0
                                    • a new high
                                      1
                                      • was hoping to collect below 370... maybe not today
                                        0
                                        • Spilt $$ into 2 package. 1. Buy now2. Buy if it drops to the suport lvl.
                                          0
                                      • illumina and roche, which one is better?
                                        0
                                        • illumina when talking about values!
                                          0
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.